Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | HPGD | P15428 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | HTR7 | P34969 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL891454 | 0.95 | LMNA (0.69) | LMNAHPGDALDH1A1MAPTTSHR | |
| SCHEMBL891366 | 0.88 | LMNA (0.64) | LMNAHPGDALDH1A1MAPTTSHR | |
| SCHEMBL30947438 | 0.88 | LMNA (0.78) | LMNAHPGDALDH1A1MAPTTSHR | |
| Hydrochloric Acid SCHEMBL2985946 | 0.87 | LMNA (0.62) | LMNAHPGDALDH1A1MAPTTSHR | |
| SCHEMBL30704400 | 0.84 | LMNA (0.68) | LMNAHPGDALDH1A1MAPTTSHR | |
| SCHEMBL2149024 | 0.84 | LMNA (0.68) | LMNAHPGDALDH1A1MAPTTSHR | |
| SCHEMBL1838349 | 0.84 | RAB9A (0.70) | LMNAHPGDALDH1A1MAPTTSHR | |
| SCHEMBL2149671 | 0.84 | LMNA (0.68) | LMNAHPGDALDH1A1MAPTTSHR | |
| SCHEMBL24709107 | 0.83 | LMNA (0.66) | LMNAHPGDALDH1A1MAPTTSHR | |
| SCHEMBL8134198 | 0.83 | LMNA (0.66) | LMNAHPGDALDH1A1MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2268273-B1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON PHARMACEUTICALS INC (US) | 2017-06-28 | — | — | EP | claimed |
| EP-1986622-B1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORP (US) | 2013-10-02 | — | — | EP | claimed |
| US-7772266-B2 | treating or preventing benign prostatic hyperplasia, enlarged prostate, acute urinary retention with 2-Isopropyl-5-methyl-cyclohexanecarboxylic acid (2-amino-2-phenyl-ethyl)-amide; agonists or antagonists of a transient receptor potential proteins; anticarcinogenic agent | DENDREON CORPORATION (US) | 2010-08-10 | — | — | US | claimed |
| US-7741355-B2 | Small-molecule modulators of TRP-p8 activity | DENDREON CORPORATION (US) | 2010-06-22 | — | — | US | claimed |
| US-20080255185-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2008-10-16 | — | — | US | claimed |
| US-20070232603-A1 | Small-molecule modulators of TRP-P8 activity | DENDREON CORPORATION (US) | 2007-10-04 | — | — | US | claimed |
| EP-2268273-B1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON PHARMACEUTICALS INC (US) | 2017-06-28 | — | — | EP | disclosed |
| US-8618155-B2 | Small-molecule modulators of Trp-p8 activity | DENDREON CORPORATION (US) | 2013-12-31 | — | — | US | disclosed |
| US-8614243-B2 | Small-molecule modulators of Trp-p8 activity | DENDREON CORPORATION (US) | 2013-12-24 | — | — | US | disclosed |
| EP-1986622-B1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORP (US) | 2013-10-02 | — | — | EP | disclosed |
| EP-2510925-A2 | Small-Molecule modulators of TRP-P8 activity | DENDREON CORPORATION (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20120225871-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120083493-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2012-04-05 | — | — | US | disclosed |
| US-7772266-B2 | treating or preventing benign prostatic hyperplasia, enlarged prostate, acute urinary retention with 2-Isopropyl-5-methyl-cyclohexanecarboxylic acid (2-amino-2-phenyl-ethyl)-amide; agonists or antagonists of a transient receptor potential proteins; anticarcinogenic agent | DENDREON CORPORATION (US) | 2010-08-10 | — | — | US | disclosed |
| US-7741355-B2 | Small-molecule modulators of TRP-p8 activity | DENDREON CORPORATION (US) | 2010-06-22 | — | — | US | disclosed |
| US-20080255185-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2008-10-16 | — | — | US | disclosed |
| US-20070232603-A1 | Small-molecule modulators of TRP-P8 activity | DENDREON CORPORATION (US) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232603-A1 | Small-molecule modulators of TRP-P8 activity | TRPC4, TRPC3, TRPC1 | LMNA 2271/4885HPGD 1644/4885ALDH1A1 4789/4885 |
| US-20080255185-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | TRPC4, TRPC3, TRPC1 | LMNA 2271/4885HPGD 1644/4885ALDH1A1 4789/4885 |
| US-20120225871-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | TRPC4, TRPC3, TRPC1 | LMNA 2271/4885HPGD 1644/4885ALDH1A1 4789/4885 |
| US-20120083493-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | TRPC4, TRPC3, TRPC1 | LMNA 2271/4885HPGD 1644/4885ALDH1A1 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.